Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin L Lampson

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Cancer|August 16, 2016
Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy developmentBenjamin L Lampson, Mizuki Nishino, Suzanne E Dahlberg, et al.
Current Biology : CB|December 19, 2012
Rare codons regulate KRas oncogenesisBenjamin L Lampson, Nicole L K Pershing, Joseph A Prinz, et al.
Blood|February 23, 2017
Ventricular arrhythmias and sudden death in patients taking ibrutinibBenjamin L Lampson, Lijian Yu, Robert J Glynn, et al.
Cancer Research|June 29, 2012
Targeting eNOS in pancreatic cancerBenjamin L Lampson, S Disean Kendall, Brooke B Ancrile, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2022
Rare Germline <i>ATM</i> Variants Influence the Development of Chronic Lymphocytic LeukemiaBenjamin L Lampson, Aditi Gupta, Svitlana Tyekucheva, et al.
Cell|April 26, 2024
Positive selection CRISPR screens reveal a druggable pocket in an oligosaccharyltransferase required for inflammatory signaling to NF-κBBenjamin L Lampson, Ana S Ramίrez, Marta Baro, et al.
Blood Advances|April 11, 2019
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemiaBenjamin L Lampson, Haesook T Kim, Matthew S Davids, et al.
The Lancet. Oncology|September 17, 2021
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 studyMatthew S Davids, Benjamin L Lampson, Svitlana Tyekucheva, et al.
Blood|June 2, 2016
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicityBenjamin L Lampson, Siddha N Kasar, Tiago R Matos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2025
Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Cancer|August 16, 2016
Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy developmentBenjamin L Lampson, Mizuki Nishino, Suzanne E Dahlberg, et al.
Current Biology : CB|December 19, 2012
Rare codons regulate KRas oncogenesisBenjamin L Lampson, Nicole L K Pershing, Joseph A Prinz, et al.
Blood|February 23, 2017
Ventricular arrhythmias and sudden death in patients taking ibrutinibBenjamin L Lampson, Lijian Yu, Robert J Glynn, et al.
Cancer Research|June 29, 2012
Targeting eNOS in pancreatic cancerBenjamin L Lampson, S Disean Kendall, Brooke B Ancrile, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2022
Rare Germline <i>ATM</i> Variants Influence the Development of Chronic Lymphocytic LeukemiaBenjamin L Lampson, Aditi Gupta, Svitlana Tyekucheva, et al.
Cell|April 26, 2024
Positive selection CRISPR screens reveal a druggable pocket in an oligosaccharyltransferase required for inflammatory signaling to NF-κBBenjamin L Lampson, Ana S Ramίrez, Marta Baro, et al.
Blood Advances|April 11, 2019
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemiaBenjamin L Lampson, Haesook T Kim, Matthew S Davids, et al.
The Lancet. Oncology|September 17, 2021
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 studyMatthew S Davids, Benjamin L Lampson, Svitlana Tyekucheva, et al.
Blood|June 2, 2016
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicityBenjamin L Lampson, Siddha N Kasar, Tiago R Matos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2025
Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Pageof 3